1. Diehl AM. Nonalcoholic Steatohepatitis. Semin Liv Dis 1999; 19: 221-9.
2. Daniel
S
, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M.
Prospective evaluation of unexplained chronic liver transaminase abnor-malties in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-4.
3. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
4. Ludwig J, Viggiano RT, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 342-8.
5. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45.
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hematology 1990; 12:
1106-10.
7. Younossi ZM, Matteoni CA, Gramlich T ve ark. Patient characteristics predicting cirrhosis and death in non-alcoholic steatohepatitis. Hematology 1998; 28: 303A.
8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough A. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
9. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hematology 1999; 29: 664-9.
10. Bugianesi E, Leone N, Vanni E ve ark. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
11. Valenti L, Fracanzani AL, Dongiovanni P ve ark. Tumor necrosis factor a promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
|
Duman DG, Tözün N | Nonalkolik Yağlı Karaciğer: Karaciğerin En Sık Görülen Hastalığı
12. Day CP, James OFW. Steatohepatitis: A tale of two "hits"? Gastroente-
rology 1998; 114: 842-5.
13. Marchesini G, Brizi M, Bianchi G. Non-alcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
14. Maher JJ. Cytokines: Overview. Semin Liv Dis 1999; 19(2): 109-15.
15. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor a in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
16. Valenti L, Fracanzani AL, Dongiovanni P ve ark. Tumor necrosis factor a promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
18. Mendler MH, Bouillet P, Le Sidaner A ve ark. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol 1998; 28: 785-94.
19. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenol 1998; 171: 659-64.
20. Sanyal A. AGA technical review on nonalcoholic fatty liver disease.
Gastroenterology 2002; 123: 1705-25.
21. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural
history of nonalcoholic fatty liver: A follow up study. Hepatology 1995;
22: 1714-9.
22. Day CP, James OFW. Hepatic steatosis: Innocent bystander or guilty
party? Hepatology 1998; 27: 1463-6.
23. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity.
Gastroenterology2002; 123: 882-932.
24. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steato-hepatitis: What we know in the new millennium. Am J Gastroenterol
2002; 97: 2714-24.
25. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH,
Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonal¬coholic hepatitis. Am J Gastroenterol 2001; 96: 519-25.
26. Marchesini G, Brizi M, Giampaola B. Metformin in non-alcoholic
hepatitis. Lancet 2001; 358: 893-4.
27. Laurin J, Lindor KD, Crippin JS ve ark. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot
study. Hepatology 1996; 23: 1464-7.
28. Başaranoğlu M, Acbay Ö, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. Am J Gast-
roenterol 1999; 31: 384.
29. D'Sauza-Gburek SM, Batts KP, Nikias GA, Wiesner RH, Krom RAF. Liver transplantation for jejunoileal bypass-associated cirrhosis. Liver Transplant Surg 1997; 3: 23-7.
30. James O, Day C. Non-alcoholic steatohepatitis: another disease of aff¬luence. Lancet1999; 353: 1634-6.
31. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
Thank you for copying data from http://www.arastirmax.com